Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Unknown 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Philadelphia Chromosome 1Neoplasm, Residual 1Leukemia, Myeloid, Chronic-Phase 1Leukemia, Myeloid, Acute 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Biphenotypic, Acute 1

Interventions

Cyclophosphamide 72fludarabine phosphate 64Peripheral Blood Stem Cell Transplantation 64Busulfan 50Cyclosporine 48Mycophenolic Acid 45Tacrolimus 41Antilymphocyte Serum 41Radiotherapy 37Whole-Body Irradiation 33Methotrexate 33Filgrastim 33Imatinib Mesylate 27Methylprednisolone 25Cord Blood Stem Cell Transplantation 24Melphalan 22Dasatinib 16sargramostim 15Etoposide 15nilotinib 14Cytarabine 14Interferon-alpha 13Therapeutics 11Flow Cytometry 11Cyclosporins 11Thiotepa 9Sirolimus 9Alemtuzumab 9Polymerase Chain Reaction 8Psychiatric Rehabilitation 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Leukemia, Myeloid, Chronic-Phase × flumatinib × Clear all
NCT04677439 2022-03-16

Flumatinib in CML-CP Patients With Ph+ Post Imatinib Failure

Shenzhen Second People's Hospital

Phase 4 Unknown
200 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Chronic-Phase

Data powered by HemOnc (CC BY 4.0) Colophon âš¡